Literature DB >> 18443737

Recombinant Listeria monocytogenes expressing an immunodominant peptide fails to protect after intravaginal challenge with herpes simplex virus-2.

William J Muller1, Nural N Orgun, Lichun Dong, David M Koelle, Meei-Li Huang, Sing Sing Way.   

Abstract

Recombinant Listeria monocytogenes expressing a type-common herpes simplex virus (HSV) gB-peptide was shown previously to protect against footpad inoculation with HSV-1. We tested this construct for protection against vaginal challenge with HSV-2. Primed mice demonstrated strong recall responses, had modest reductions in HSV-2 DNA in vaginal mucosa, but were not protected from disease.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18443737      PMCID： PMC2635120          DOI： 10.1007/s00705-008-0089-7

Source DB:  PubMed          Journal:  Arch Virol        ISSN： 0304-8608            Impact factor:   2.574


  29 in total

1.  Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2.

Authors:  E L Parr; M B Parr
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes.

Authors:  D M Koelle; C M Posavad; G R Barnum; M L Johnson; J M Frank; L Corey
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

3.  Effects of the estrous cycle on local humoral immune responses and protection of intranasally immunized female mice against herpes simplex virus type 2 infection in the genital tract.

Authors:  W S Gallichan; K L Rosenthal
Journal:  Virology       Date:  1996-10-15       Impact factor: 3.616

4.  Homing in on the cellular immune response to HSV-2 in humans.

Authors:  David M Koelle; Julio C Gonzalez; Andrew S Johnson
Journal:  Am J Reprod Immunol       Date:  2005-04       Impact factor: 3.886

5.  The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant.

Authors:  M E Wallace; R Keating; W R Heath; F R Carbone
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

6.  Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.

Authors:  L Corey; A G Langenberg; R Ashley; R E Sekulovich; A E Izu; J M Douglas; H H Handsfield; T Warren; L Marr; S Tyring; R DiCarlo; A A Adimora; P Leone; C L Dekker; R L Burke; W P Leong; S E Straus
Journal:  JAMA       Date:  1999-07-28       Impact factor: 56.272

7.  The genome sequence of herpes simplex virus type 2.

Authors:  A Dolan; F E Jamieson; C Cunningham; B C Barnett; D J McGeoch
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

8.  Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization.

Authors:  W S Gallichan; K L Rosenthal
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

9.  Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity.

Authors:  J E Blaney; E Nobusawa; M A Brehm; R H Bonneau; L M Mylin; T M Fu; Y Kawaoka; S S Tevethia
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

10.  Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples.

Authors:  A J Ryncarz; J Goddard; A Wald; M L Huang; B Roizman; L Corey
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948
View more
  4 in total

1.  Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine.

Authors:  Xavier Dervillez; Chetan Gottimukkala; Khaled W Kabbara; Chelsea Nguyen; Tina Badakhshan; Sarah M Kim; Anthony B Nesburn; Steven L Wechsler; Lbachir Benmohamed
Journal:  Future Virol       Date:  2012-04-01       Impact factor: 1.831

2.  A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections.

Authors:  Flavia Chiuppesi; Laura Vannucci; Anna De Luca; Michele Lai; Barbara Matteoli; Giulia Freer; Roberto Manservigi; Luca Ceccherini-Nelli; Fabrizio Maggi; Mauro Bendinelli; Mauro Pistello
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

3.  Herpes simplex virus-2 glycoprotein interaction with HVEM influences virus-specific recall cellular responses at the mucosa.

Authors:  Sarah J Kopp; Christopher S Storti; William J Muller
Journal:  Clin Dev Immunol       Date:  2012-05-14

4.  Different routes of bacterial infection induce long-lived TH1 memory cells and short-lived TH17 cells.

Authors:  Marion Pepper; Jonathan L Linehan; Antonio J Pagán; Traci Zell; Thamotharampillai Dileepan; P Patrick Cleary; Marc K Jenkins
Journal:  Nat Immunol       Date:  2009-11-22       Impact factor: 25.606
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.